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The COVID-19 pandemic is an unprecedented challenge and will require novel
therapeutic strategies. Affected patients are likely to be at risk of arrhythmia due
to underlying comorbidities, polypharmacy and the disease process. Importantly, a
number of the medications likely to receive significant use can themselves, particularly
in combination, be pro-arrhythmic. Drug-induced prolongation of the QT interval is
primarily caused by inhibition of the hERG potassium channel either directly and/or
by impaired channel trafficking. Concurrent use of multiple hERG-blocking drugs may
have a synergistic rather than additive effect which, in addition to any pre-existing
polypharmacy, critical illness or electrolyte imbalance, may significantly increase the risk
of arrhythmia and Torsades de Pointes. Knowledge of these risks will allow informed
decisions regarding appropriate therapeutics and monitoring to keep our patients safe.
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INTRODUCTION
The novel coronavirus disease of 2019 (COVID-19) pandemic is uncharted territory for clinicians
and healthcare systems alike. The potential for a high volume of severely unwell patients creates
a significant challenge. In particular, the combination of severe infection, respiratory dysfunction,
sepsis, shock, and/or haemodynamic instability (1–3) present significant potential for myocardial
injury and potentially dangerous arrhythmia. Not only do these pathophysiological states promote
the formation of arrhythmia, but unstable arrhythmia could present a significant threat to this
cohort of patients who are at risk of haemodynamic instability.
Due to the potential strain on healthcare systems, it is likely that non-specialists will be involved
in the management of COVID-19 patients including those experiencing arrhythmia. Similarly,
clinicians may face situations where they are using multiple concurrent medications with which
they may not be entirely familiar. Here, we attempt to summarize how the use of multiple different
types of medication could contribute (synergistically, in some instances) to increase arrhythmic
risk. In particular, we focus on the risk of drug-induced QT interval prolongation (commonly
referred to as acquired long QT syndrome; aLQTS) which is a serious issue for many of the
medications which are likely to be used.
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While the use of drugs known to prolong the QT interval
may well be necessary and unavoidable, an awareness and
understanding of this risk should guide additional safety
measures such as monitoring of the corrected QT interval
(QTc) on 12-lead electrocardiogram (ECG) measurement. For
cases of a prolonged QT interval there is a risk, particularly
with a rate-corrected QT interval (QTc) of >500ms (4), of
dangerous arrhythmia including Torsades de Pointes (TdP);
close monitoring and involvement of specialist cardiology input
should be sought, as well as minimizing, where possible, the use
of other known QT-prolonging medication.
INCREASED BASELINE ARRHYTHMIC
RISK IN COVID-19 PATIENTS
From the data available, COVID-19 seems to cause more serious
disease in older patients and those with comorbidities (1–
3, 5–7). Zhou et al. (3) described hypertension, diabetes and
coronary heart disease as the three most prevalent comorbidities
in COVID-19 patients from two hospitals at the epicenter
of the initial outbreak in Wuhan. Not only were these
comorbidities associated with a significantly worse outcome,
they are also, in combination with advanced age, significant
risk factors for arrhythmia. Increasing age and co-morbidities
also increase the likelihood of pre-existing polypharmacy, which
may prove problematic in the context of additional potentially
QT-prolonging medication. Unfortunately, published data of
COVID-19 patient cohorts to date do not seem to include any
ECG or specific arrhythmia data, although no doubt we will
gain a better picture as our understanding of the disease and its
management evolves.
INCREASED ARRHYTHMIC RISK OF
COVID-19 INFECTION
SARS-CoV-2 is thought to gain entry to human host cells via
the angiotensin converting enzyme 2 (ACE2) receptor, which is
highly expressed in the heart and lungs and to which the viral
spike protein has high affinity (8, 9). Interestingly, data during the
previous SARS-CoV outbreak demonstrated ACE2-dependent
cardiac infection and inflammation in both mouse and human
hearts (10). The down-regulation of affected ACE2 receptors was
suggested as a potential contributory factor to SARS-associated
myocarditis and subsequent cardiomyopathy, with inflammation
and fibrosis likely to provide a substrate for arrhythmia.
The risk of arrhythmia is likely to increase with the
development of significant infection, and increase as the severity
of the infection and/or systemic inflammatory response increases
(11). Significant myocardial damage and fulminant myocarditis
have been described (2, 3, 5), and cardiac arrest associated with
ventricular arrhythmia (as well as non-shockable rhythms) is
reported (7). Du et al. reported some form of arrhythmia present
in 60% of a group of fatal cases, with cardiac arrest or malignant
arrhythmia listed as the cause of death for over 10% of cases (12).
There is increasing awareness of the development in severely
unwell patients of a hyperinflammatory state or cytokine
storm (13) which can lead to multi-organ failure. Recent
work strongly suggests this hypercytokinemia (in particular
elevated levels of interleukin-6) further increases arrhythmic risk
via multiple mechanisms, including, notably, hERG blockade
(14) and QT prolongation (15, 16). Myocarditis itself is a
heterogenous condition associated with a number of arrhythmic
states including bradyarrhythmia and atrial or ventricular
tachyarrhythmia (17). Data are urgently needed to describe the
unique arrhythmic challenges of COVID-19 myocarditis.
Additionally, the multiple medications likely to receive
significant use (antibiotics, anesthetic agents, anti-arrhythmic
agents, and potentially specific agents to target COVID-19
such as anti-malarial or anti-viral medications) may indeed
contribute to a pro-arrhythmic state in a patient group already
at risk. Importantly, the additional risk of QT prolongation
with some potential combinations of these medications may
be synergistic rather than simply additive, due largely to their
unique mechanisms of ion channel blockade. Finally, significant
electrolyte disturbances, common in unwell patients, will further
exacerbate arrhythmic risk (18).
CLINICAL MANAGEMENT OF COVID-19:
SIGNIFICANT POTENTIAL FOR hERG
BLOCKADE AND QT PROLONGATION
The hERG (or “Kv11.1”) potassium channel (encoded by human
Ether-à-go-go Related Gene; alternative nomenclature KCNH2)
mediates the rapid component of cardiac delayed rectifier K+
current (also known as IKr). Briefly, this channel is crucial
to the repolarization phase of the cardiac action potential;
we recommend an excellent review article (19). Inhibition of
hERG is considered to be the most common and important
mechanism of drug-induced QT prolongation (20, 21) and
occurs through direct pharmacological channel block and/or
impaired trafficking of hERG channels to the cell membrane.
Consequently, hERG testing is a requirement during novel drug
development: indeed, prolongation of the QT interval (and its
association with dangerous TdP) has been the biggest cause of
restriction or withdrawal of drugs already on the market (21–23).
Importantly, recent data including work from our group
suggests that the effect on hERG (and thus on QT-prolongation)
of multiple drugs may not be simply additive but synergistic (24,
25) (i.e., an effect in excess of the sum of their individual parts).
This is particularly relevant when considering an older patient
group who may already be taking hERG-blocking medication.
In particular, the antimalarial medications chloroquine and
hydroxychloroquine (26, 27) are receiving particular attention
as antiviral agents: these drugs are multichannel blockers with
particular effects on hERG and Kir2.1 and are likely to cause
significant QT prolongation at the concentrations effective
against SARS-CoV-2 in vitro (28–30), especially when combined
with other antivirals (such as lopinavir/ritonavir) or antibiotics
(macrolides and fluroquinolones being particularly notable) (26).
Further information should be sought regarding novel antiviral
agents (31) currently undergoing clinical trials; for example,
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TABLE 1 | A list of medications which could be used in the management of
COVID-19 which are also associated with risk of QT prolongation.
Type of medication Drugs
Anesthetic agents Propofol, sevoflurane







Anti-arrhythmics Amiodarone, flecainide, ibutilide,
procainamide, quinidine, sotalol
Anti-psychotics (used for delirium) Haloperidol, quetiapine, risperidone
Other potential therapies under
consideration
Antimalarials such as chloroquine,
hydroxychloroquine or mefloquine
List intended to be illustrative as to risks and is not exhaustive. Further up to date
information can be found online from trusted sources (www.crediblemeds.org). *possible
rather than established risk.
favipiravir has been associated with QT interval prolongation in
a case report (32) and remdesivir awaits comprehensive testing.
Combination therapy with azithromycin and
hydroxychloroquine is undergoing testing at present (33, 34).
Notably, part of a Brazilian study comparing low vs. high dose
chloroquine, in combination with ceftriaxone and azithromycin
with or without oseltamivir, was terminated early due to
safety concerns; with 25% of those in the high-dose arm
showing QT prolongation (vs. 11% in the low-dose arm) and
two patients in the high-dose arm experiencing ventricular
tachycardia prior to death (35). Similarly, the head of a French
cardiology unit reported they had prematurely terminated
their hydroxychloroquine-azithromycin COVID-19 trial due
to unacceptable QT prolongation (36). The randomized
DisCoVeRy (NCT04315948), SOLIDARITY (EudraCT Number
2020-000982-18), and RECOVERY (EudraCT Number 2020-
001113-21) studies will provide important evidence regarding
the effectiveness and safety of various antiviral and antimalarial
drugs in the treatment of COVID-19 patients (37).
Online resources can be consulted to clarify which drugs are
associated with QT prolongation (see www.crediblemeds.org).
Table 1 lists medications associated with QT prolongation which
may be commonly used in the management of COVID-19 [as
taken from the updated WHO management guidance (38) with
additions from authors’ clinical experience from UK practice].
The list is not exhaustive but attempts to highlight potential
areas of risk when using these medications, as well as their use
in combination.
DISCUSSION
The recent publication by Ackerman et al. of urgent guidance
and a practical flow-chart regarding safe use of QT-prolonging
medication is very welcome, and should be consulted as an aid
to manage risk in the setting of QT prolongation (39), as should
the Heart Rhythm Society (HRS) Task Force update (40). Other
resources provide valuable guidance for clinicians dealing with
specific patient populations: those with congenital heart disease
(41) or inherited arrhythmia syndromes (42). Of note, a case
report has reported significant QT prolongation (620ms) in a
patient with COVID-19 treated with multiple hERG blocking
medications (including levofloxacin, hydroxychloroquine and
azithromycin), which was successfully managed with drug
cessation and intravenous lignocaine (43). Separately, mexiletine
has also been suggested to be effective in treating TdP associated
with acquired long QT syndrome (44).
COVID-19 represents a step into the unknown: not only are
we grappling to come to terms with effective management of
this new disease, but so too with safe use of these treatments.
Effective therapy will be welcome, but the use of multiple drugs in
combination has to be exercised with caution as it may increase
the risk of QT prolongation and Torsades de Pointes, largely via
pharmacological hERG blockade. Knowledge of this risk enables
clinicians to ensure adequate monitoring of the QT interval
and management of arrhythmic risk, maximizing safety for our
patients in this challenging time.
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